CUA Highlights of GU ASCO 2022 - Prostate Cancer Session - French

Canadian Urological Association (CUA)

English - February 22, 2022 05:00 - 47 minutes - 108 MB
Medicine Health & Fitness Science Life Sciences medicine urologic urology Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: CUA Practice Changing Publications (PCP) - Endourology (Surgical Management of BPH)

Next Episode: CUA Q & A Series | Bone Health Management in Prostate Cancer - David Kendler

Disclosures:

Anil Kapoor
Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca
Speakers Bureau: Merck, Ipsen, Eisai
Investments: Verity, Point Biopharma
Clinical Trials: CCTG, Eisai, Janssen, Merck
Leadership/Board Position

Tamim Niazi
Honoraria/ research funding: Abbvie, Astellas, Bayer, Janssen, Sanofi, Merck, AstraZeneca, TerSera, Knight Therapeutics, Amgen, Tolmar, Sanofi, Ferring

Krista Noonan
Consultancy-Astellas, AstraZeneca, EMD Serono, Janssen, Pfizer

Ricardo Rendon

Advisory Board: Astellas, Amgen, Abbvie, AstraZeneca, Bayer, Ferring, Janssen, Sanofi, TerSera

Speakers' Bureau: Amgen, Astellas, Bayer, Ferring, Janssen,

Grant/Honorarium: Astellas, Amgen, Bayer Janssen

Clinical Trial: Abbvie, Amgen, Astellas, AstraZeneca, Ferring, Janssen, Pfizer, Sanofi, Myovant